Clinical Trials Logo

Conjunctivitis, Allergic clinical trials

View clinical trials related to Conjunctivitis, Allergic.

Filter by:

NCT ID: NCT02166268 Completed - Clinical trials for Grass Pollen Induced Allergic Rhinoconjunctivitis

Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber

AV-G-03
Start date: June 2014
Phase: Phase 2
Study type: Interventional

The clinical trial will investigate the efficacy of Avanz Phleum pratense in the treatment of rhinitis in an environmental challenge chamber.

NCT ID: NCT02161146 Completed - Clinical trials for Conjunctivitis, Allergic

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

Start date: June 4, 2014
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.

NCT ID: NCT02148744 Completed - Atopic Dermatitis Clinical Trials

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Start date: May 2014
Phase: Phase 1
Study type: Interventional

This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, ascending dose study to investigate the safety, tolerability, and pharmacokinetics of XmAb7195 in adult healthy volunteers and in adult subjects with elevated IgE levels.

NCT ID: NCT02132169 Completed - Clinical trials for Atopic Disease (Including Allergic Conjunctivitis)

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Start date: May 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).

NCT ID: NCT02131051 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis

Start date: June 2010
Phase: N/A
Study type: Observational

This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin Allergy Nasal Spray and Eye drops. In addition the effectiveness and safety shall be compared to Azelastine containing nasal Sprays and Eye drops. The patient applied Ectoin® Rhinitis Nasal Spray / Eye drops or takes Azelastine nasals spray and eye drops according to the instructions for use. The observation takes place over a period of 7 days. Response to treatment is recorded at day 7 by the physician and in daily by the patient in a dairy.

NCT ID: NCT02082899 Completed - Clinical trials for Allergic Conjunctivitis

A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

Start date: February 2014
Phase: Phase 2
Study type: Interventional

This is a Phase II Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC) Model and Conjunctival Allergen Provocation Test (CAPT) Model. Approximately 150 subjects will be enrolled and randomized in one study center in Canada for a duration of 0.33 years.

NCT ID: NCT02082262 Completed - Clinical trials for Conjunctivitis, Allergic

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

Start date: March 2014
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.

NCT ID: NCT02079649 Completed - Clinical trials for Allergic Conjunctivitis

Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.

NCT ID: NCT02069535 Completed - Clinical trials for Allergic Rhinoconjunctivitis

An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy

Start date: April 2014
Phase: Phase 2
Study type: Interventional

This trial is an open, national, multi-centre trial. The main objective of this trial is to assess the tolerability of the up-dosing phase of AVANZ® Cupressus arizonica by measurement of related Adverse Events.

NCT ID: NCT02065856 Completed - Clinical trials for Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen

An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy

AV-X-02
Start date: December 2013
Phase: Phase 2
Study type: Interventional

This trial is an open, national, multi-centre trial. The trial will be initiated in December 2013 and subjects will receive treatment for 6 weeks. Safety monitoring will be performed in an ongoing basis through a Clinical Safety Group with immediate access to Adverse Events registered in the clinical database. The composition, procedures and deliverables of the Clinical Safety Group will be detailed in a Safety Agreement prior to trial start.